A Shanghai-based brain-computer interface startup has just completed two massive funding rounds in quick succession, raising nearly $100 million and reshaping how the industry thinks about BCIs and artificial intelligence working together. Gestala, which develops ultrasound-based brain-computer interfaces, closed its Angel+ round with RMB 420 million (roughly $58 million) just four months after its initial Angel round, according to reporting from VCBeat. The dual funding achievement is unusual in the BCI space, where most companies operate under traditional medical device valuation models with much lower funding ceilings.

The company's rapid capital accumulation reflects something deeper than typical investor enthusiasm. Gestala is positioning itself not as a single-purpose medical device maker, but as a platform company exploring the intersection of brain-computer interfaces and artificial intelligence to fundamentally understand human intelligence itself. This philosophical and technical shift explains why the startup has invested heavily in establishing a Shanghai headquarters dedicated to AI Brain Foundation Model research, placing it on equal strategic footing with its global headquarters in Chengdu.

What Makes Gestala's Approach Different From Other BCI Companies?

Most brain-computer interface companies focus narrowly on solving specific medical problems, like restoring movement to paralyzed patients or managing chronic pain. Gestala is doing that too, but it's layering in something more ambitious. The company's business model operates like a three-tier bucket, with disease treatment and patient care forming the foundation, BCI-AI integration research in the middle, and broader application development at the top.

The clinical results are already compelling. In U.S. clinical trials, Gestala's ultrasonic brain-computer interface reduced chronic pain levels by 50 percent, with effects lasting one to two weeks. The company expects to release its first-generation product to the public by the end of 2026, with plans to complete domestic registration and market launch within one to two years. These timelines suggest the technology is moving from research into real-world deployment faster than many observers expected.

But the real innovation lies in the middle tier of Gestala's strategy. The company is exploring how BCI and AI technologies can work together not just to decode brain signals more accurately, but to achieve something far more ambitious: a comprehensive analysis and full simulation of human brain intelligence. This is where the philosophical dimension enters the picture.

"Neuroscience and artificial intelligence are two sides of the same coin," explained Peng Lei, founder of Gestala.

Peng Lei, Founder of Gestala

Peng's framing captures a crucial insight: neuroscience and AI are not separate fields competing for resources and attention. They are complementary paths to understanding and defining intelligence itself. Nearly all core AI algorithms, from convolutional neural networks to reinforcement learning and attention mechanisms, have drawn foundational inspiration from how the human brain works. Conversely, AI tools are now enabling neuroscience research to process massive, multimodal datasets and solve signal acquisition challenges that were previously intractable.

How Does Gestala Plan to Bridge Neuroscience and AI?

The company's strategy rests on a specific technical and philosophical principle: only when neuroscience models and AI models can be mutually mapped and interpreted can humanity truly understand intelligence itself. This requires several interconnected capabilities:

• Signal Acquisition and Processing: Developing ultrasound-based BCIs that can capture brain activity with high fidelity and minimal invasiveness, generating the high-quality data needed to train AI models.
• AI Foundation Models for Neuroscience: Building specialized AI models trained on brain data that can identify patterns, predict outcomes, and simulate neural processes with accuracy comparable to biological systems.
• Bidirectional Feedback: Using AI insights to refine neuroscience understanding, and using neuroscience discoveries to improve AI architectures and training methods.
• Clinical Validation: Testing these integrated approaches in serious medical scenarios where data quality is high and safety requirements are stringent, ensuring models generalize from patients to healthy individuals.

This approach explains why Gestala has invested so heavily in AI research despite being a hardware and medical device company. The ultrasound BCI is the foundation, but the AI Brain Foundation Model is the engine that transforms raw brain data into actionable intelligence.

Why This Matters Beyond Medicine

If Gestala succeeds in achieving comprehensive analysis and simulation of human brain intelligence, the implications extend far beyond chronic pain management or treating neurological disease. The company's leadership envisions applications spanning disease prediction, health management, longevity medicine, drug development, and personalized treatment protocols. Each of these represents a multi-billion-dollar market opportunity.

The philosophical underpinning is equally important. Peng has cited Immanuel Kant's observation that two things fill the mind with wonder: the starry heavens above and the moral law within. The former reflects questions about consciousness and life in the universe; the latter pertains to what makes humans uniquely human and different from other animals. Both questions ultimately point toward understanding human intelligence. By pursuing this understanding through the lens of BCI-AI integration, Gestala is positioning itself at the intersection of neuroscience, philosophy, and technology.

The funding success and strategic investments suggest that major investors believe this vision is achievable within a reasonable timeframe. Whether Gestala can deliver on this ambitious roadmap remains to be seen, but the company's rapid capital accumulation and technical progress indicate the field is moving faster than many skeptics anticipated.

" }